Voltaren Emulgel gel for external use

Land: Armenië

Taal: Engels

Bron: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Productkenmerken Productkenmerken (SPC)
01-07-2020

Werkstoffen:

diclofenac (diclofenac diethylamine)

Beschikbaar vanaf:

GlaxoSmithKline Consumer Healthcare S.A.

ATC-code:

M02AA15

INN (Algemene Internationale Benaming):

diclofenac (diclofenac diethylamine)

Dosering:

10mg/g

farmaceutische vorm:

gel for external use

Eenheden in pakket:

20g, 50g and 100g laminated tube

Prescription-type:

OTC

Autorisatie-status:

Registered

Autorisatie datum:

2019-01-09

Productkenmerken

                                GSK Consumer Healthcare S.A.,
Switzerland.
Summary of Product Characteristics
Global Labeling
VOLTAREN
Gel
Diclofenac diethylamine 1.16%
SUMMARY OF PRODUCT CHARACTERISTICS
Document status:
FINAL
Release date:
10 Oct 2019
Number of pages:
8
GSK Consumer Healthcare S.A.,
Switzerland.
Summary of Product Characteristics
TABLE OF CONTENTS
1
NAME OF THE MEDICINAL PRODUCT
.......................................................................
3
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
............................................. 3
3
PHARMACEUTICAL FORM
............................................................................................
3
4
CLINICAL PARTICULARS
..............................................................................................
3
4.1
Pharmacotherapeutic group
.....................................................................................
3
4.2
Posology and method of administration
.................................................................. 4
4.3
Contraindications
.....................................................................................................
4
4.4
Special warnings and precautions for use
................................................................ 5
4.5
Interaction with other medicinal products and other forms of
interaction .............. 5
4.6
Pregnancy and lactation
...........................................................................................
5
4.7
Effects on ability to drive and use machines
........................................................... 5
4.8
Undesirable effects
..................................................................................................
6
4.9
Overdose
..................................................................................................................
7
PHARMACOLOGICAL PROPERTIES
...................................................................................
7
4.3
Pharmacodynamic properties
...................................................................................
7
                                
                                Lees het volledige document
                                
                            

Documenten in andere talen

Bijsluiter Bijsluiter Russisch 01-07-2020

Zoekwaarschuwingen met betrekking tot dit product